Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolomic effects of dexmedetomidine in parturients and fetuses undergoing cesarean section
ChiCTR2500096233Phase 4Not yet recruiting
- Sponsor
- Tianjin Central Hospital of Obstetrics and Gynecology
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexmedetomidine (2 arms), sponsored by Tianjin Central Hospital of Obstetrics and Gynecology. Primary endpoint: Untargeted metabolomics. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
dexmedetomidine
Beyond the preview
Go deeper on ChiCTR2500096233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096233.